No abstract

In this paper, the improvement of casting properties of the high-strength AlZnMgCu alloys is described. This improvement was achieved by additions of Ni, Mg, and Si, which formed eutectic phases, thus reducing the crystallization interval of the alloy. The comparison of the castability and hot-tearing tendency was made for three alloys: nearly single-phase AlZn6Mg2 alloy, quasi-ternary eutectic AlZn7Mg7Cu1Ni3Si3 alloy, and common casting AlSi10 alloy. It was shown that the castability and hot-tearing tendency of the quasi-ternary eutectic alloy are similar to those of the AlSi alloy.

According to Industry 4.0 the process of digitization in manufacturing companies has advanced to the virtualization phase. The final state should be a complete virtualization of the production plant. However, virtualization has a high demand for innovation. This article summarizes the findings of the implementation of the "Digital Twin" methodology in a real manufacturing company. The main topic is virtualization of heavy machine tools of Skoda Machine Tool Co. For the virtualization are used modern software tools Siemens NX, Mechatronic Concept Designer, Simit and VNCK kernel.

Background This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS). Methods Patients aged C18 years with advanced or metastatic solid tumors were enrolled in a 3 ? 3 design with S-1 dose escalation (two planned cohorts) performed according to the occurrence of dose-limiting toxicity (DLT). On day 1 of each 21-day cycle, patients received epirubicin 50 mg/m 2 followed by oxaliplatin 130 mg/m 2 (maximum 8 cycles) and then S-1 [20 mg/m 2 (cohort 1) or 25 mg/m 2 (cohort 2), twice daily]: first dose, evening of day 1; subsequent administration on days 2-14, twice daily; last dose, morning of day 15 (unlimited number of S-1 cycles). After protocol amendment, enrollment in a third cohort was restricted to patients with chemotherapynaïve advanced or metastatic esophagogastric cancer. Results DLT was reported for two of the five patients in cohort 2, defining 20 mg/m 2 twice daily as the MTD of S-1 combined with epirubicin and oxaliplatin in heavily pretreated patients. Thirteen patients with chemotherapy-naïve advanced or metastatic esophagogastric cancer were subsequently enrolled and treated at an S-1 dose level of 25 mg/m 2 twice daily; no DLTs were reported; median overall survival was 13.1 months. Of the 11 evaluable patients, three (27 %) had partial responses and seven (64 %) had stable disease. The safety profile was in line with expectations. Conclusions The promising activity of EOS (S-1 dose level, 25 mg/m 2 twice daily) and acceptable safety profile support further clinical development of this combination for the first-line treatment of patients with advanced or metastatic esophagogastric cancer.

This paper deals with virtual prototyping and optimization of heavy machine tools. Main focus is on static and dynamic stiffness of heavy lathe. Analysis of virtual models of heavy lathes is very specific because the great influence on machine stiffness has workpiece and machine base. In most cases the weight of workpiece is greater than the weight of machine tool. The influence of workpiece and machine base on static and dynamic stiffness of heavy lathe is analysed in this work. CAx software Siemens NX 10.0 is used for numerical analysis and optimization of heavy lathe.